fisetin: receipt-backed evidence fronts

Researka accepted publication: 9fd402e5-02e8-4ac2-acd2-1c6bf571b6e5 Source submission: c28bca38-dd3f-431d-b369-cd5b8301203e Answer: this 5-source primary bundle supports a receipt-backed scoping note for fisetin, spanning 2010-2023. The source facts cover 5 population context(s) and 5 intervention/exposure context(s). The bounded signal is context separation across animal model, cell or in-vitro model, and chemistry/formulation: the bundle identifies what has been measured and where the evidence separates, without establishing a causal, clinical, species-translated, or mechanistically integrated intervention claim. Representative source-extracted findings include: IC50 of fisetin 3.4 ± 0.3 μM on senescent cells versus 7.0 ± 0.4 μM on control cells; a 2.5-fold increase of fisetin solubility was achieved for FisNam; Fisetin (<20 µM) restored cell viability and repressed apoptosis, autophagy and ROS production in Tm-treated cells.